<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of pericardial effusion and acute pericarditis during pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of pericardial effusion and acute pericarditis during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of pericardial effusion and acute pericarditis during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Massimo Imazio, MD, FESC, FHFA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin M LeWinter, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jae K Oh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although diseases of the pericardium occur sporadically during pregnancy, there is no evidence that pregnancy increases the susceptibility to pericardial diseases [<a href="#rid1">1</a>]. The outcomes of pregnancies in women with pericardial disease are similar to those expected in the general population. More complex cases may require a multidisciplinary approach involving different subspecialties (eg, cardiology, internal medicine, maternal-fetal medicine, and neonatology).</p><p>Limited data are available to guide the management of pericardial disease during pregnancy. However, as with pregnancy in general, the major tenet of avoiding all medications and interventions that are not absolutely necessary should be followed.</p><p>This topic will discuss the clinical features, diagnosis, and management of pericardial effusion and acute (or recurrent) pericarditis during pregnancy. A broader discussion of pericardial disease in the general population is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis"</a> and  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H1519581022"><span class="h1">PERICARDIAL EFFUSION</span></p><p class="headingAnchor" id="H2998517899"><span class="h2">Fetal pericardial fluid</span><span class="headingEndMark"> — </span>After 20 weeks of gestation, a small amount of pericardial fluid (&lt;3 mm) can be detected in the normal fetus by fetal ultrasound [<a href="#rid1">1,2</a>]. Larger fetal pericardial effusions should raise suspicion of disease conditions, such as nonimmune hydrops fetalis, fetal hemolytic disease due maternal antibodies to Rh or other red cell antigens, structural anomaly (eg, heart or diaphragm, teratoma), chromosomal abnormality, infection, or an immunopathy [<a href="#rid3">3,4</a>]. Because of the limited distensibility of the fetal pericardial sac, pathologic pericardial effusion may be the first sign of hydrops, detectable before the appearance of ascites, pleural effusion, and soft tissue edema. (See  <a class="medical medical_review" href="/z/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Fetal findings'</a>.)</p><p class="headingAnchor" id="H2"><span class="h2">Maternal pericardial effusion</span></p><p class="headingAnchor" id="H3878252106"><span class="h3">Epidemiology and clinical features</span><span class="headingEndMark"> — </span>Pericardial effusion has been reported in the first and second trimester in 15 to 20 percent of pregnancies and in approximately 40 percent of pregnant women during the third trimester [<a href="#rid5">5</a>]. In general, these effusions are asymptomatic, benign, transient, and resolve spontaneously without therapy. In the absence of signs or symptoms of acute pericarditis or cardiac tamponade, neither diagnostic testing (generally with echocardiography) nor specific treatment is required.</p><p>The following observations have been made regarding pericardial effusions in pregnancy:</p><p class="bulletIndent1"><span class="glyph">●</span>The effusion is usually small to moderate in size, with separation of the pericardial layers of less than 10 mm. When sampled, these effusions are usually found to be a transudate (hydropericardium) [<a href="#rid5">5-8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slightly elevated blood pressure and/or nonspecific ST-T changes have been reported in association with pericardial effusion [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical examination and electrocardiogram (ECG) are generally normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pericardial effusion is usually transient and disappears within two months following delivery [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of signs or symptoms of acute pericarditis or cardiac tamponade, treatment is not required [<a href="#rid5">5-8</a>]. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p></p><p>The signs and symptoms of cardiac tamponade may be masked during pregnancy due to the physiologic increase in circulating blood volume. This may lead to a larger pericardial effusion being present before signs or symptoms are detected.</p><p class="headingAnchor" id="H1480417706"><span class="h3">Management and follow-up</span><span class="headingEndMark"> — </span>For pregnant women who are identified as having a moderate or large pericardial effusion that is not felt to require immediate drainage, serial follow-up testing with echocardiography should be performed. Echocardiography examination should include Doppler recording of mitral inflow velocities and hepatic vein flow velocities as well as M-mode and 2D echocardiography to assess the hemodynamic impact of pericardial effusion. In general, if the patient remains asymptomatic and hemodynamically stable and the effusion is not increasing in size, we continue with serial echocardiograms every three months until the pericardial effusion is decreasing in size or resolved. For pregnant women with a small asymptomatic pericardial effusion, we repeat the echocardiogram only if clinically indicated by signs or symptoms suggestive of possible pericardial tamponade, as small pericardial effusions are usually benign and spontaneously resolve. </p><p class="headingAnchor" id="H5"><span class="h1">ACUTE PERICARDITIS</span></p><p class="headingAnchor" id="H2430687457"><span class="h2">Epidemiology and etiology</span><span class="headingEndMark"> — </span>There are no published data on the frequency of acute pericarditis in pregnancy. There is no evidence to suggest an incidence that is higher or lower than in the general population. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Epidemiology'</a>.)</p><p>As in the general population, idiopathic acute pericarditis is the most frequent final diagnosis  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 1</a>); the etiology is often presumed to be viral [<a href="#rid9">9</a>]. Infectious etiologies other than viral are less common than in the general population. Tuberculous pericarditis should be suspected especially in cases coming from endemic areas or in case of HIV infection [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">"Etiology of pericardial disease"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Acute pericarditis can present in a variety of ways, depending on the underlying etiology. Patients with an infectious etiology may present with signs and symptoms of systemic infection such as fever and leukocytosis. Viral etiologies in particular may be preceded by "flu-like" respiratory or gastrointestinal symptoms. Patients with a known autoimmune disorder or malignancy may present with signs or symptoms specific to their underlying disorder. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Clinical features'</a>.)</p><p>The major clinical manifestations of acute pericarditis include [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain – Typically sharp and pleuritic, improved by sitting up and leaning forward.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial friction rub – A superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ECG changes – New widespread ST elevation and/or PR depression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion.</p><p></p><p class="headingAnchor" id="H4288365607"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of acute pericarditis is usually suspected based on a history of characteristic pleuritic chest pain, and is confirmed if a pericardial friction rub, typical ECG changes, or an effusion is present. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly [<a href="#rid10">10</a>]. Additional testing, which typically includes blood work, chest radiography, electrocardiography, and echocardiography, can support the diagnosis but is frequently normal or unrevealing. The electrocardiogram is usually the first and one of the most helpful diagnostic tests in patients with chest pain and suspected acute pericarditis. Because ST segment elevations in a patient with chest pain may also be seen in patients with an acute coronary syndrome, careful evaluation of all ECG findings is critical. Echocardiography is often normal, but it is an essential part of the evaluation if there is evidence of an associated pericardial effusion and/or signs of cardiac tamponade. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Diagnosis'</a>.)</p><p>The diagnosis of acute pericarditis in pregnancy is made using the same criteria  (<a class="graphic graphic_table graphicRef74376" href="/z/d/graphic/74376.html" rel="external">table 2</a>) as in the general population [<a href="#rid10">10,13</a>]. Echocardiography is the imaging method of choice for diagnosis, evaluating the hemodynamic impact of pericardial fluid, absence of regional wall motion (when STEMI is considered), guidance for pericardiocentesis when needed, and follow-up [<a href="#rid14">14</a>].</p><p>Diagnostic radiographs of the chest, if indicated, produce almost no scatter to the fetus; any radiation received would not result in a measurably increased risk, especially if the maternal abdomen is shielded. However, in clinical practice, they are avoided in most cases.</p><p>Magnetic resonance imaging with gadolinium and nuclear isotope scans with gallium-67 are generally avoided unless necessary to significantly improve diagnostic performance and improve fetal or maternal outcome. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p class="headingAnchor" id="H3049705511"><span class="h2">Determination of risk and need for hospitalization</span><span class="headingEndMark"> — </span>Many clinicians admit all new cases of acute pericarditis to the hospital, but this may not be necessary. A pregnant patient with uncomplicated acute pericarditis can undergo initial evaluation in a same-day hospital facility or clinic, although outpatient follow-up is required [<a href="#rid15">15,16</a>]. On the other hand, pregnant patients with high-risk features are at increased risk of short-term complications and have a higher likelihood of a specific disease, as is also the case in nonpregnant patients [<a href="#rid15">15</a>]. Hospital admission is indicated for high-risk patients to initiate appropriate therapy and a thorough etiologic evaluation. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Assessment of risk and need for hospitalization'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Management</span><span class="headingEndMark"> — </span>The management of pregnant women with acute pericarditis is similar to that in the general population , with the notable exception that the impact of all therapies on the fetus must be considered  (<a class="graphic graphic_algorithm graphicRef108392" href="/z/d/graphic/108392.html" rel="external">algorithm 1</a>). General outcomes of pregnancy in patients with pericarditis are good when the mothers are followed by a multidisciplinary team with experience in the field [<a href="#rid17">17-19</a>].</p><p>In addition to activity restriction, the therapy of acute pericarditis should be targeted as much as possible to the underlying etiology [<a href="#rid20">20-24</a>]. In patients with an identified cause other than viral infection, specific therapy appropriate to the underlying disorder is indicated  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 1</a>). However, in resource-rich countries, most cases of acute pericarditis in immunocompetent patients are idiopathic and considered to be most likely due to a viral infection.</p><p>Because of the relatively benign course associated with the common causes of pericarditis (&gt;80 percent of cases), it is at not necessary to search for the etiology in all patients. As such, most patients are initially treated for a presumptive viral cause with nonsteroidal antiinflammatory drugs (NSAIDs), which can generally be continued until gestational week 20, as discussed below. (See <a class="local">'NSAID therapy'</a> below.)</p><p>Most patients with acute pericarditis can be managed effectively with medical therapy alone. However, patients with a large pericardial effusion, a hemodynamically significant pericardial effusion, a suspicion of a bacterial or neoplastic etiology, or evidence of constrictive pericarditis should be evaluated for invasive therapies, such as pericardial drainage and/or pericardiotomy (pericardial window). (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Adjunctive therapies'</a>.)</p><p class="headingAnchor" id="H2966768961"><span class="h3">Activity restriction</span><span class="headingEndMark"> — </span>Strenuous physical activity may trigger a recurrence of symptoms in patients with acute (or recurrent) pericarditis; therefore, such activity should be avoided at least until symptom resolution or preferably for two to three months following the cessation of symptoms. The approach to reintroduction of physical activities is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Activity restriction'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Initial treatment</span><span class="headingEndMark"> — </span>The general approach to the pharmacologic management of acute (or recurrent) pericarditis during pregnancy  (<a class="graphic graphic_algorithm graphicRef108392" href="/z/d/graphic/108392.html" rel="external">algorithm 1</a>) is somewhat similar to that for nonpregnant individuals. Patients with a specific cause identified should have treatment tailored to that specific etiology, while patients with idiopathic pericarditis should receive antiinflammatory therapy, with the exception that <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> is not used in pregnant patients. (See <a class="local">'Colchicine'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an identified cause other than viral or idiopathic disease, specific therapy appropriate to the underlying disorder is indicated  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In acute viral or idiopathic pericarditis, the optimal approach to therapy varies before and after gestational week 20 due to the impact of NSAIDs on the ductus arteriosus in the second half of gestation  (<a class="graphic graphic_algorithm graphicRef108392" href="/z/d/graphic/108392.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant women who are less than 20 weeks pregnant, we recommend NSAIDs, either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (500 to 750 mg every eight hours) or <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (600 to 800 mg every eight hours). (See <a class="local">'NSAID therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant women at gestational week 20 week or greater, NSAIDs are contraindicated and should not be started (or should be withdrawn if already in use). In this population, glucocorticoids are the preferred therapy as they have not been associated with congenital anomalies after the first trimester, and neonatal adrenal suppression is rare. Generally, low to moderate glucocorticoid doses are used and are sufficient to control the disease. Inducing maternal gestational diabetes is a potential concern. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Glucocorticoids'</a>.)</p><p></p><p>As is true for the use of all drugs during pregnancy, treatment of acute pericarditis must balance the benefits of therapy against the potential harm to the fetus. A list of common antiinflammatory and immunosuppressive drugs used in the treatment of pericardial diseases is provided  (<a class="graphic graphic_table graphicRef52475" href="/z/d/graphic/52475.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef63892" href="/z/d/graphic/63892.html" rel="external">table 4</a>).</p><p>One of the largest reports of pregnant women with pericarditis includes six cases (mean age 30 years, mean gestational age at delivery 38 weeks, and mean birth weight 2839 g), all with an idiopathic etiology [<a href="#rid25">25</a>]. Four women were treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 800 mg three times daily with gradual tapering in three within 20 weeks of gestation. In one case, aspirin was continued until delivery. All women were treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a low to moderate dose (eg, 10 to 25 mg daily), in four cases during all the pregnancy and in two cases starting at the third trimester. Five pregnancies (83 percent) were uneventful; HELLP syndrome developed in the mother who was treated with aspirin until delivery. (See  <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p>In another series, 21 pregnancies were evaluated in 14 women with a history of recurrent idiopathic pericarditis (mean maternal age 31.5 years, mean gestational age 39.0 weeks) [<a href="#rid18">18</a>]. Ten pregnancies were uneventful, three ended in spontaneous early abortion, and one fetal death occurred at 19 weeks. Recurrences of pericarditis occurred in eight and were treated by adding NSAIDs in two cases; in five cases the dose of corticosteroids was increased, and in two cases <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> was started/increased; paracetamol was always allowed. <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> was used in two cases in the prospective cohort. HELLP syndrome occurred in one patient, which resolved after delivery, and one patient experienced arterial hypertension and elevated transaminase. All infants had a good outcome (mean birth weight 3114 g, 10 males). In the retrospective cohort, birth weight was significantly lower (2806 g versus 3320 g) when higher doses of corticosteroids (median dose respectively 10.0 mg versus 2.5 mg) were used. Five recurrences of pericarditis occurred after delivery, easily treated with standard therapy.</p><p class="headingAnchor" id="H10"><span class="h4">NSAID therapy</span><span class="headingEndMark"> — </span>NSAIDs are not teratogenic and can be safely used during the first trimester and the first part of the second trimester. After gestational week 20, all NSAIDs (except <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> at less than 100 mg/day) can cause constriction of the ductus arteriosus and impair fetal renal function leading to oligohydramnios, and the risk seems to increase dramatically after week 28. Thus, aspirin and other NSAIDs, excluding COX-2 inhibitors, can be continued until the first part of the second trimester but should be withdrawn beginning at 20 weeks of gestation [<a href="#rid13">13</a>]. Because there are insufficient safety data on selective COX-2 inhibitors, these medications should be avoided during pregnancy.</p><p>For pregnant women who are less than 20 weeks pregnant, we recommend NSAIDs rather than glucocorticoids as the initial treatment. The 2015 European Society of Cardiology (ESC) guidelines recommend high-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (500 to 750 mg every eight hours) as the first choice of therapy, although other NSAIDs are allowed [<a href="#rid13">13</a>]. There is no evidence that <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> is inferior to aspirin, and therefore it may also be used as first-line therapy. The initial administration of an NSAID should be at a full dose (ie, "attack dose") every six to eight hours to achieve better symptom control than with a lower dose  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>). The attack dose is maintained empirically for one to two weeks or until complete symptom resolution. Tapering should be considered following the attack dose in an attempt to reduce the subsequent risk of recurrence. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Nonsteroidal antiinflammatory drugs'</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>As glucocorticoids are not teratogenic (although there may be a small increase in the risk of cleft palate when used in the first trimester), they are often used in the setting of pericarditis during pregnancy, especially if the patient is refractory to NSAIDs or is more than 20 weeks pregnant. In general, however, for patients who are less than 20 weeks pregnant, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or NSAIDs should be the initial treatment of choice [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Glucocorticoids'</a>.)</p><p>Our approach to glucocorticoid dosing has been endorsed by the 2015 ESC guidelines favoring low to moderate doses  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>) [<a href="#rid13">13</a>]. In our experience, rapid tapering of systemic glucocorticoids increases the risk of treatment failure and recurrence.</p><p>We usually begin tapering glucocorticoids at two to four weeks, after resolution of symptoms and/or C-reactive protein normalization. Each decrement in <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should proceed only if the patient is asymptomatic, particularly for doses lower than 25 mg/day. A proposed tapering scheme follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose 15 to 25 mg – Taper 2.5 mg/day every two to four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose &lt;15 mg – Taper 1.25 to 2.5 mg/day every two to six weeks</p><p></p><p><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> and <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> are metabolized by the placenta into inactive 11-keto forms, and only 10 percent of the active drugs may reach the fetus [<a href="#rid26">26</a>]. Prednisone and prednisolone appear to be reasonable therapies if used at low to medium doses (eg, 10 to 25 mg daily) and are reasonable choices when glucocorticoids are required [<a href="#rid25">25</a>]. Rarely, maternal use of systemic glucocorticoids during first-trimester of pregnancy may lead to a small increase in orofacial clefts, from approximately 1:1000 births in the general population to a possible increase of three or four for every 1000 births [<a href="#rid27">27</a>]. A more extensive discussion of the risks of glucocorticoid therapy during pregnancy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H12"><span class="h4">Colchicine</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> during pregnancy and lactation should be discussed with the mother if its use is important to control recurrent pericarditis or if it is indicated to treat a specific condition (eg, familial Mediterranean fever) [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Breast feeding</span><span class="headingEndMark"> — </span>Following delivery, breastfeeding infants may be exposed to the medications if they are excreted into breast milk. Among the usual therapies prescribed for acute pericarditis in pregnancy, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> has the greatest potential for harm in infants due to the theoretical risk of Reye syndrome. (See  <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">"Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'</a>.)</p><p>Most NSAIDs are excreted into human breast milk, although generally in very small quantities. Several NSAIDs, including flufenamic acid, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>, <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">mefenamic acid</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, and <a class="drug drug_general" data-topicid="9781" href="/z/d/drug information/9781.html" rel="external">piroxicam</a> are considered consistent with breastfeeding by the American Academy of Pediatrics [<a href="#rid28">28</a>]. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> (&gt;100 mg/day) should be considered with caution (and preferably avoided) because of potential adverse effects for the infant [<a href="#rid13">13,28</a>]. A useful practice may be to postpone the NSAID dose until after breastfeeding in order to reduce the infant's exposure, although the 2015 ESC guidelines state that aspirin is "preferably avoided" during breastfeeding [<a href="#rid13">13,17</a>].</p><p>Breastfeeding is feasible during corticosteroid therapy, but should be postponed (four hours) with doses &gt;40 mg/day [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H16"><span class="h1">PLANNING FOR PREGNANCY</span><span class="headingEndMark"> — </span>Women with recurrent pericarditis on therapy should be evaluated carefully prior to any planned pregnancy. Pregnancy should be planned in a phase of disease quiescence. In women with chronic recurrent pericarditis, pregnancy should be avoided during a period of disease activity. (See  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p class="headingAnchor" id="H3368241936"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118887.html" rel="external">"Society guideline links: Management of cardiovascular diseases during pregnancy"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion has been reported in the first and second trimester in 15 to 20 percent of pregnancies and in approximately 40 percent of pregnant women during the third trimester. In general, these effusions are asymptomatic, benign, transient, and resolve spontaneously without therapy. In the absence of signs or symptoms of acute pericarditis or cardiac tamponade, neither diagnostic testing (eg, follow-up echocardiography) nor specific treatment is required. (See <a class="local">'Epidemiology and clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For pregnant women who are identified with a moderate or large pericardial effusion that is not felt to require immediate drainage, serial follow-up testing with echocardiography should be performed every three months until resolved. For pregnant women with a small asymptomatic pericardial effusion, we repeat the echocardiogram only if clinically indicated by signs or symptoms suggestive of possible pericardial tamponade. (See <a class="local">'Management and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of acute pericarditis is usually suspected based on a history of characteristic pleuritic chest pain and confirmed if a pericardial friction rub, characteristic ECG, or pericardial effusion is present. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly. The diagnosis of acute pericarditis in pregnancy is made using the same criteria  (<a class="graphic graphic_table graphicRef74376" href="/z/d/graphic/74376.html" rel="external">table 2</a>) as in the general population. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of pregnant women with acute pericarditis is similar to that in the general population  (<a class="graphic graphic_algorithm graphicRef108392" href="/z/d/graphic/108392.html" rel="external">algorithm 1</a>), with the notable exception that the impact of all medical therapies on the fetus must be considered. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Strenuous physical activity may trigger recurrence of symptoms in patients with acute (or recurrent) pericarditis; therefore, such activity should be avoided until symptom resolution. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Activity restriction'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with an identified cause other than viral or idiopathic disease, specific therapy appropriate to the underlying disorder is indicated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant women who are less than 20 weeks pregnant, we suggest nonsteroidal antiinflammatory drugs (NSAIDs) rather than glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (500 to 750 mg every eight hours) or <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (600 to 800 mg every eight hours). (See <a class="local">'NSAID therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant women at gestational week 20 week or greater, NSAIDs are contraindicated and should not be started (or should be withdrawn if already in use). In this population, glucocorticoids are the preferred therapy, as their use during pregnancy at low to moderate doses is considered reasonable. (See <a class="local">'Glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> during pregnancy and lactation should be discussed with the mother if its use is important to control recurrent pericarditis or there is an underlying disease to control (eg, familial Mediterranean fever). (See <a class="local">'Colchicine'</a> above and  <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">"Management of familial Mediterranean fever", section on 'Pregnancy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Spodick DH. Pericardial disorders during pregnancy. In: The pericardium: a comprehensive textbook, Dekker, New York 1997. p.89.</li><li><a class="nounderline abstract_t">Dizon-Townson DS, Dildy GA, Clark SL. A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies. Obstet Gynecol 1997; 90:958.</a></li><li><a class="nounderline abstract_t">Mohan MS, Patole SK. Isolated fetal pericardial effusion: case report and review of the literature. Aust N Z J Obstet Gynaecol 2002; 42:216.</a></li><li><a class="nounderline abstract_t">Kyeong KS, Won HS, Lee MY, et al. Clinical outcomes of prenatally diagnosed cases of isolated and nonisolated pericardial effusion. Fetal Diagn Ther 2014; 36:320.</a></li><li><a class="nounderline abstract_t">Abduljabbar HS, Marzouki KM, Zawawi TH, Khan AS. Pericardial effusion in normal pregnant women. Acta Obstet Gynecol Scand 1991; 70:291.</a></li><li><a class="nounderline abstract_t">Halphen C, Haiat R, Clément F, Michelon B. [Silent pericardial effusion in late pregnancy: echocardiographic detection in the third trimester of pregnancy (author's transl)]. J Gynecol Obstet Biol Reprod (Paris) 1982; 11:245.</a></li><li><a class="nounderline abstract_t">Haiat R, Halphen C. Silent pericardial effusion in late pregnancy: a new entity. Cardiovasc Intervent Radiol 1984; 7:267.</a></li><li><a class="nounderline abstract_t">Enein M, Zina AA, Kassem M, el-Tabbakh G. Echocardiography of the pericardium in pregnancy. Obstet Gynecol 1987; 69:851.</a></li><li><a class="nounderline abstract_t">Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2007; 118:286.</a></li><li><a class="nounderline abstract_t">Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007; 93:1176.</a></li><li><a class="nounderline abstract_t">Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.</a></li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77:429.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Clinical management of acute pericardial disease: a review of results and outcomes. Ital Heart J 2004; 5:803.</a></li><li><a class="nounderline abstract_t">Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.</a></li><li><a class="nounderline abstract_t">Brucato A, Pluymaekers N, Tombetti E, et al. Management of idiopathic recurrent pericarditis during pregnancy. Int J Cardiol 2019; 282:60.</a></li><li><a class="nounderline abstract_t">Serati L, Carnovale C, Maestroni S, et al. Management of acute and recurrent pericarditis in pregnancy. Panminerva Med 2021; 63:276.</a></li><li><a class="nounderline abstract_t">Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Derosa FG, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown) 2009; 10:217.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:785.</a></li><li><a class="nounderline abstract_t">Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA 2015; 314:1498.</a></li><li><a class="nounderline abstract_t">Brucato A, Imazio M, Curri S, et al. Medical treatment of pericarditis during pregnancy. Int J Cardiol 2010; 144:413.</a></li><li><a class="nounderline abstract_t">Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81:936.</a></li><li><a class="nounderline abstract_t">Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.</a></li><li class="breakAll">https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (Accessed on July 01, 2016).</li></ol></div><div id="topicVersionRevision">Topic 4934 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spodick DH. Pericardial disorders during pregnancy. In: The pericardium: a comprehensive textbook, Dekker, New York 1997. p.89.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397111" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069155" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Isolated fetal pericardial effusion: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278095" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical outcomes of prenatally diagnosed cases of isolated and nonisolated pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746251" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pericardial effusion in normal pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7108157" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Silent pericardial effusion in late pregnancy: echocardiographic detection in the third trimester of pregnancy (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6529728" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Silent pericardial effusion in late pregnancy: a new entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574815" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Echocardiography of the pericardium in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502574" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Indicators of poor prognosis of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049636" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Triage and management of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17890693" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001332" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004992" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633435" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical management of acute pericardial disease: a review of results and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712713" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anti-inflammatory and immunosuppressive drugs and reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773267" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of idiopathic recurrent pericarditis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687181" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of acute and recurrent pericarditis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177006" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Controversial issues in the management of pericardial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19262208" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Aetiological diagnosis in acute and recurrent pericarditis: when and how.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736783" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925146" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Medical therapy of pericardial diseases: part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26461998" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation and Treatment of Pericarditis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327851" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Medical treatment of pericarditis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5086721" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The transplacental passage of prednisone and prednisolone in pregnancy near term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
